HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An urchin-like helical polypeptide-asparaginase conjugate with mitigated immunogenicity.

Abstract
The use of asparaginase (ASNase), a first line drug for lymphoma treatment, is impaired by short circulation and notoriously high immunogenicity. Although PEGylation can prolong the circulating half-life of ASNase, however, it also induces anti-PEG antibodies that lead to accelerated blood clearance (ABC) and hypersensitivity reactions. Here, we create an urchin-like polypeptide-ASNase conjugate P(CB-EG3Glu)-ASNase, in which the surface of ASNase is sufficiently shielded by an array of zwitterionic helical polypeptides through the labeling of the ε-amine of lysine. The conjugate is fully characterized with size exclusion chromatography, SDS-PAGE, dynamic light scattering, and circular dichroism. In vitro, P(CB-EG3Glu)-ASNase retains full activity based on the enzymatic assay using the Nessler's reagent and cell viability assay. In vivo, examination of the enzyme activity in serum indicates that P(CB-EG3Glu)-ASNase prolongs the circulating half-life of ASNase for ~20 fold. Moreover, P(CB-EG3Glu)-ASNase significantly inhibits tumor growth in a xenografted mouse model using human NKYS cells. Importantly, P(CB-EG3Glu)-ASNase elicits almost no antidrug or antipolymer antibodies without inducing ABC effect, which is in sharp contrast with a similarly produced PEG-ASNase conjugate that develops both antidrug/antipolymer antibodies and profound ABC phenomenon. Our results demonstrate that urchin-like conjugates are outstanding candidates for reducing immunogenicity of therapeutic proteins, and P(CB-EG3Glu)-ASNase holds great promises for the treatment of various lymphoma diseases.
AuthorsYali Hu, Dedao Wang, Hao Wang, Ruichi Zhao, Yaoyi Wang, Yunfei Shi, Jun Zhu, Yan Xie, Yu-Qin Song, Hua Lu
JournalBiomaterials (Biomaterials) Vol. 268 Pg. 120606 (01 2021) ISSN: 1878-5905 [Electronic] Netherlands
PMID33360506 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2020 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies
  • Antineoplastic Agents
  • Peptides
  • Asparaginase
Topics
  • Animals
  • Antibodies (pharmacology)
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Asparaginase (pharmacology, therapeutic use)
  • Cell Survival
  • Mice
  • Peptides (pharmacology)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: